Not long ago, tiny Aquinox Pharmaceuticals was trading at under $2.00; at $1.84, to be specific.1 Then something incredible happened… The company released positive mid-stage clinical trial results on their bladder pain drug.
Twitter went mad. The stock took off. By that afternoon, shares had traded up as much as 500%.2 Over the next two weeks nearly 18 million shares changed hands – roughly 90 times the stock’s 30-day average. By that Friday Aquinox hit a high of $22.13, a gain of 1,103%.3
Another stock, Celator Pharmaceuticals, recently jumped over 600% on positive Phase 3 results. That move took just seven days.4 Then Incyte Corp. went from $2.54 to $131 – a leap of 5,057% – on a series of positive news.5 And a whole slew of others have rewarded investors just as much. Spectacular profits, to be sure, and not as rare as you might think.
The trick, of course, is finding stocks that are about to soar…
RepliCel (OTCQB: REPCF / TSX.V: RP) could potentially achieve what no one else has been able to do before now.
Until advancements in stem cell therapy, there was no way for your body’s soft tissues to heal themselves effectively.6
This represents a monumental advance in the medical world.
The company’s scientists are figuring out how to use YOUR OWN CELLS to GROW HEALTHY NEW TISSUE.
RepliCel is pioneering the use of collagen-producing cells deep within your hair follicle to heal collagen-rich tissues such as aging skin and damaged tendons, as well as highly specialized cells to regrow hair for those suffering from pattern baldness.
Collagen represents 30-40% of all your body’s proteins, and is essential to the health of skin, tendons, hair, membranes, and connective tissue.7
It is the substance that holds your body together, and the breakdown of collagen is associated with numerous health conditions.
RepliCel is developing a way to deliver NEW COLLAGEN right within your own body, by taking a minute number of your healthy cells and replicating them in a lab, then reintroducing them into your body at the site of damage.
The result is “self-healing” tissues, with the goal of little to zero scar tissue or other hindrances to full function.
Nothing like this has been done before. The science is new, and it could be worth billions.
Right now Replicel has :
 | The continued advancement of three groundbreaking cell-based therapies based on positive data received to date. |
| An exclusive marketing license with global giant Shiseido of Japan, the fourth largest cosmetics and personal care company in the world; Shiseido is entirely financing clinical research ongoing now on RepliCel’s hair restoration therapy |
| A brand new proprietary next-generation dermal injector device with broad applications in the $3.2 billion facial rejuvenation market |
The Shiseido deal gives us confidence that the company’s technology and market potential are significant. After all, Shiseido doesn’t do business with any fly-by-night or unpromising company.
And with the continued advancement of these three products, you could see an increase in demand for the company’s stock.
Be sure to take immediate action and add RepliCel to your watch list, as this could be your best chance to profit from this regenerative medicine company.
“On the cusp of a revolution”
In 2012, the Nobel Prize in Medicine went to two scientists who discovered that certain mature cells can be reprogrammed to become new, immature cells capable of developing into any tissues in your body.8
That discovery was the extension of a revolution that is changing the future of medicine today, as scientists around the world race to develop cell-based therapies capable of REGENERATING HEALTHY TISSUE.
But while these two Nobel scientists and their colleagues were working on cell reprogramming, RepliCel’s researchers were leveraging a much simpler idea: find cells with a desired function, remove a few of them, grow millions more, and put them back into the patient where the cells’ function is designed to help the body heal itself.
Since the early 2000s, RepliCel’s scientists had been investigating cells hidden within the hair follicle as robust agents for regrowing hair and producing collagen, the primary protein in skin and tendons.
By 2003, they had discovered that your body’s dermal sheath cup (DSC) cells could induce NEW hair fiber growth, something once thought impossible.
Since then, RepliCel has discovered that other cells grown from your own dermal sheath can regenerate new skin and new tendons by producing the collagen that makes up these tissues. 9,10
That was the beginning…
Today RepliCel – an emerging biotech company well on its way to what could be a tremendous success story – is at the forefront of the regenerative medicine field.
That’s because cell-based medical therapies are the FUTURE.
| The journal Science Translational Medicine calls cell-based therapeutics “the next pillar of medicine.” They say, “Today, biomedicine sits on the cusp of a new revolution: the use of microbial and human cells as versatile therapeutic engines.”11 |
| Mahendra Rao, director of the National Institutes of Health’s new Intramural Center for Regenerative Medicine says that cell therapies “could be paradigm-shifting for the healthcare field.”12 |
| Wendell Lim, PhD, director of the UCSF Center for Systems and Synthetic Biology, says that today we are “on the cusp of a revolution.”13 |
| The University of California at San Francisco says that “Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals.”14 |
Cell-based therapies are now being called the “third pillar” of medicine. First came small-molecule drugs produced by Big Pharma. Next came the genetic engineering revolution and targeted drugs developed by biotech firms. Finally, we have cell-based technologies.
Just like genetic engineering was a disruptive technology several decades ago, cell therapy is disrupting the medical landscape today.
The ability to regenerate tissue means that conditions can potentially be treated, not just managed, as has been the case with nearly all past drugs and biologic agents.
New technology puts your own cells to work to repair and rejuvenate your body
RepliCel (OTCQB: REPCF / TSX.V:RP) is working on unlocking the unique biological function of your body’s key cells to regenerate tissue.
Working tirelessly in their labs, company scientists discovered that the dermal sheath of your hair follicles is an excellent source of fibroblasts, the cells in connective tissue that produce collagen.
These cells are about five times more prolific than skin cells in their production of type 1 collagen, the major cell structure of skin and tendons.15
Collagen also plays a big part in renewing cells, and is responsible for maintaining the strength and elasticity of tendons and skin.
But your body’s ability to produce collagen decreases from around the age of 30. This is what gives you wrinkles and leads to weakness in your tendons.
RepliCel aims to create therapies for conditions related to diminished collagen by generating new collagen-producing cells in a laboratory and then injecting them into targeted areas.
Two of the company’s products are for conditions where there are too few healthy fibroblasts, such as chronic tendinosis and damaged skin.
The third product is their treatment for pattern baldness, where there is a deficit of dermal sheath cup cells that are responsible for maintaining the hair fiber within the follicle.
Those cells are easily isolated and replicated under lab conditions.
RepliCel has developed cell manufacturing technology and procedures to commercialize these products. They have also developed specialized delivery devices which have unique potential for licensing for other medical and cosmetic uses.
And because tissue is regenerated from your body’s own cells, it means RepliCel’s risk profile may be lower than with most other drugs and biologics today. That translates to SHORTER CLINICAL TRIAL TIMELINES and LOWER COMMERCIALIZATION COSTS.
Their breakthrough cell-based hair replacement therapy has already been PROVEN EFFECTIVE in pre-clinical and Phase 1 preliminary results. Those results show that it can be…
Preliminary results show it could be more effective than any drug or topical treatment now on market!
This new cell-based technology has the potential to become the WORLD’S FIRST minimally invasive solution for hair loss.
There are three problems with hair transplants today. First, when transplanting hair follicles from one location of your scalp to another, there are only a limited number of follicles available to harvest.
Second, hair transplantation only achieves a satisfactory result when performed by a gifted surgeon, of which there are few.18
Third, hair transplantation is not an option women have commonly pursued, and a significant population of women suffer from hair loss.19
RepliCel’s cell therapy solves those problems:
| With a cell transplant, there is no limit to the number of cells that can be grown to use in regenerating new hair fibers.21 |
| As a simple cell injection, even technicians can perform the procedure.22 |
|
The technique is as effective on women as men.23
|
Both pre-clinical and Phase 1 studies found that the procedure resulted in hair growth in an outstanding 63% of test subjects.24,25 In comparison, minoxidil (Rogaine®), the leading hair replacement treatment, regrows moderate to dense hair in only 26% of subjects.26
That means RepliCel’s therapy is likely as effective if not more than current products!
And once a person stops using Rogaine or its competitor, Propecia®, all the new hair falls out again. Treatment must continue indefinitely, which is a tremendous negative for users.59
What’s more, use of Rogaine results in an approximate 8-15% increase in hair density after 12 months of use. Propecia results are similar to Rogaine’s, with an approximate 7-14% density increase at 12 months.28
Plus, those products have serious side effects including erectile dysfunction and loss of libido.
By comparison, in early clinical testing, RepliCel’s proprietary treatment results in an average 11.8% density increase at JUST SIX MONTHS! And 70% of those responders averaged 14.3% DENSITY INCREASE! And so far, there have been no serious side effects recorded.29
Imagine what could happen when RepliCel’s technology hits the market. RepliCel could potentially own a big piece of the $3 billion hair replacement market shortly thereafter! These are all reasons why RepliCel is…
Setting up to revolutionize the $3 billion hair replacement market
The hair restoration market is valued at an enormous $3 billion a year,30 and is expected to grow by 30% a year through 2020.31
Yet current treatments are known to be only partially effective, or, in the case of surgery, time-consuming, painful, and prohibitively expensive.
In fact, the American Hair Loss Association states that, “Unfortunately, 99% of all products being marketed in the less than ethical hair loss treatment industry are completely ineffective for the majority of those who use them.”32
The hair restoration market is valued at an enormous $3 billion a year,30 and is expected to grow by 30% a year through 2020.31
Yet current treatments are known to be only partially effective, or, in the case of surgery, time-consuming, painful, and prohibitively expensive.
In fact, the American Hair Loss Association states that, “Unfortunately, 99% of all products being marketed in the less than ethical hair loss treatment industry are completely ineffective for the majority of those who use them.”32
